Evaluation of concomitant use of anticancer drugs and herbal products: From interactions to synergic activity Review
| Authors: | Berretta, M.; Dal Lago, L.; Tinazzi, M.; Ronchi, A.; La Rocca, G.; Montella, L.; Di Francia, R.; Facchini, B. A.; Bignucolo, A.; Montopoli, M. |
| Review Title: | Evaluation of concomitant use of anticancer drugs and herbal products: From interactions to synergic activity |
| Abstract: | CAM is used by about 40% of cancer patients in Western Countries, with peaks of 80% for breast cancer patients. Cancer patients use CAM to boost immune function, to control cancer symptoms and treatment-related side effects, and to improve health-related quality of life (HR-QoL) and survival. Unfortunately, self-prescription of natural remedies in cancer patients can lead to unexpected toxicities and can reduce the effectiveness of cancer therapy. Although CAM usually refers to all the “natural or organic” products/methods that are generally considered less toxic, there are concerns about drug interactions, especially in patients participating in clinical trials with experimental agents. Despite the claims of the promising and potential benefits made by prescribers, many CAMs lack clear scientific evidence of their safety and efficacy. Given the widespread use of CAM—both clearly declared and overt—in this review, we focused on the most important known data on the risk of interactions between biologics and oncology drugs with the goal of opening up CAM in accordance with the meaning of integrative medicine. © 2022 by the authors. |
| Keywords: | unclassified drug; hepatitis; sorafenib; cisplatin; doxorubicin; erlotinib; fluorouracil; diarrhea; drug potentiation; hypertension; gemcitabine; paclitaxel; adjuvant therapy; cancer patient; pancreas cancer; chemotherapy; methotrexate; temozolomide; antineoplastic agent; imatinib; quality of life; bortezomib; liver toxicity; nephrotoxicity; pharmacodynamics; breast cancer; nausea; vomiting; bendamustine; cyclophosphamide; dasatinib; risk assessment; docetaxel; irinotecan; dizziness; insomnia; drug antagonism; cardiotoxicity; ovary carcinoma; tamoxifen; nausea and vomiting; alternative medicine; herbaceous agent; laetrile; ascorbic acid; ginger extract; lycopene; sabal extract; acupuncture; migraine; vinca alkaloid; herb drug interaction; drug metabolism; platinum complex; taxane derivative; anthracycline derivative; natural product; mitomycin; tacrolimus; resveratrol; frail elderly; medicine; geriatric patient; head and neck tumor; curcumin; curcuma longa extract; polypharmacy; cytochrome p450; interactions; alternative; drug overdose; human immunodeficiency virus infected patient; cannabinoid; hypersensitivity; fungal extract; cannabis; uft; aromatherapy; silymarin; bromelain; complementary; pioglitazone; antiretroviral therapy; synergism; xenobiotic agent; silybum marianum extract; hypericum perforatum extract; ginseng extract; nutraceutical; echinacea extract; ginkgo biloba extract; yunzhi; essiac; ubidecarenone; sinecatechins; berberine; cancer; human; article; aloe vera extract; solid malignant neoplasm; glycyrrhiza glabra root; linghzi; nutrition supplement; platycodon grandiflorum extract; zeolite; medicinal mushroom; pharmacogenetic variant |
| Journal Title: | Cancers |
| Volume: | 14 |
| Issue: | 21 |
| ISSN: | 2072-6694 |
| Publisher: | MDPI |
| Date Published: | 2022-11-01 |
| Start Page: | 5203 |
| Language: | English |
| DOI: | 10.3390/cancers14215203 |
| PROVIDER: | scopus |
| PMCID: | PMC9657145 |
| PUBMED: | 36358622 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 December 2022 -- Source: Scopus |
